Clinical Trial Update: A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy [Phase 2]

View source ↗

Summary

Phase 2 study evaluating camrelizumab plus apatinib as consolidation therapy after chemoradiotherapy in locally advanced non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Apatinib (apatinib)
• Camrelizumab (camrelizumab)

Snippet

Sponsor: Chinese Academy of Medical Sciences | Conditions: Locally Advanced Non-Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN